BERLIN, 26 Oct (APM) - Sandoz Germany/Hexal (Novartis group) will align the retail price of its biosimilar of Abbvie's Humira (adalimumab) Hyrimoz with its cheapest competitor, Biogen's Imraldi, APM learned on Friday.
The price of Hyrimoz, launched on 17 October with a 21% discount to Humira (APMMA 60204), will be cut on 15 November in order to offer a 37% to 40% discount to Humira, a Sandoz/Hexal spokeswoman told APM on Friday.
It will be priced at €1,144.65 for two prefilled pens or syringes at 40 mg or €3,354.43 for a pack of six - similar to the prices of Imraldi, which was also launched on 17 October (APMMA 60190).
Sandoz Germany informed physicians about the additional discount in a letter, seen by APM, saying that the company will "take part in the price competition" between Humira biosimilars.
"As we promised, we will make you and your patients not only a qualitative, first-class offer, but also a guaranteed cost-effective one," the company wrote.
A third biosimilar was launched in Germany by Amgen, Amgevita, with a 18% discount to Humira (APMMA 60232).
German biosimilars lobby Pro Biosimiolar said last week that it expected the competition "to be intense because of the large number of competitors launching at the same time" (APMMA 60174).
All the biosimilars are approved in Europe for the same autoimmune conditions as Humira, including rheumatoid arthritis (RA); juvenile idiopathic arthritis; axial spondyloarthritis; psoriatic arthritis; psoriasis; paediatric plaque psoriasis; adult and adolescent hidradenitis suppurativa; Crohn’s disease; paediatric Crohn’s disease; ulcerative colitis; and uveitis.
Retail prices at 1 November
The retail prices of all three Humira biosimilars launched in Germany mid-October - Hyrimoz, Imraldi and Amgevita (APMMA 60232) - will be published in the pharmacists' data base Lauer-Taxe on 1 November, APM has learned.According to a pharmacists' source, the retail prices as of 1 November are following:
| Name (company) | Price 1-pack 20 mg | Price 2-pack 40 mg | Price 6-Pack 40 mg |
|---|---|---|---|
| Amgevita (Amgen) | €407.90 | €1,577.54 | €4,533.09 |
| Hyrimoz (Sandoz/Hexal) | none | €1,510.06 | €4,206.35 |
| Imraldi (Biogen) | none | €1,144.64 | €3,354.43 |
Hyrimoz's retail price as of 15 November will be :
| Price 1-pack 20 mg | Price 2-pack 40 mg | Price 6-Pack 40 mg | |
|---|---|---|---|
| Hyrimoz (Sandoz/Hexal) | none | €1,144.65 | €3,354.43 |
By way of comparison, Humira is currently priced as follows:
| Price 1-pack 20 mg | Price 2-pack 40 mg | Price 6-Pack 40 mg | |
|---|---|---|---|
| Humira (Abbvie) | €967.27 | €1,911.47 | €5,324.49 |
Humira is also marketed in an 80 mg dose in a 1-pack (prefilled pen or syringe €1,911.47) and a 3-pack (prefilled pens €5,324.49).
hm/clg
TRY APM Market Access AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to the latest stories
Our coverage includes:
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
REQUEST
an initial 10 day temporary access of APM Market Access.
